Atossa Genetics Inc Stock
Atossa Genetics Inc Stock
Atossa Genetics Inc dominated the market today, gaining €0.048 (6.560%).
With 8 Buy predictions and not the single Sell prediction the community is currently very high on Atossa Genetics Inc.
With a target price of 6 € there is potential for a 681.25% increase which would mean more than doubling the current price of 0.77 € for Atossa Genetics Inc.
So far the community has only identified positive things for Atossa Genetics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Atossa Genetics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Atossa Genetics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Atossa Genetics Inc | 6.560% | 12.610% | 8.782% | -29.799% | -20.497% | 21.021% | 7.023% |
| Aortech International plc | -0.990% | 2.564% | -1.961% | 3.627% | -10.714% | -79.757% | -94.318% |
| Theralase Technologies Inc | -1.740% | -1.744% | -21.028% | -46.519% | -47.188% | -61.591% | -34.496% |
| Medmira Inc. | 6.670% | 14.286% | 5.263% | -12.088% | -50.000% | 9.589% | - |
Comments
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.75 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ATOS provided by MarketBeat
Atossa Genetics (NASDAQ:ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.50 to $7.75. They now have a "buy" rating on the stock.
Show more
Ratings data for ATOS provided by MarketBeat
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $7.25 to $7.50. They now have a "buy" rating on the stock.
Show more
Ratings data for ATOS provided by MarketBeat